Kureyama Yuika, Hanaoka Yutaka, Tomita Daisuke, Matoba Shuichiro, Kuroyanagi Hiroya
Department of Colorectal Surgery, Toranomon Hospital, Tokyo, JPN.
Cureus. 2024 May 13;16(5):e60188. doi: 10.7759/cureus.60188. eCollection 2024 May.
BRAF V600E mutation-positive advanced recurrent colorectal cancer has a poor prognosis. Encorafenib, binimetinib, and cetuximab were approved for use to treat this cancer in 2020 in Japan. Here, we present the case of a patient with BRAF V600E mutation-positive colorectal cancer, who was treated with encorafenib, binimetinib, and cetuximab, and developed grade 3 pancreatitis at our hospital. After pancreatitis treatment, the drug doses were reduced from 300 mg to 225 mg of encorafenib and from 90 mg to 60 mg of binimetinib, and the treatment was resumed. Since then, no grade 3 or higher adverse events were observed. Although pancreatitis has been reported to occur after the use of encorafenib and binimetinib, it is rare. With appropriate dose reduction and attention to side effects, this regimen is considered feasible for the long-term treatment of BRAF V600E mutation-positive advanced recurrent colorectal cancer in patients aged >70 years.
BRAF V600E突变阳性的晚期复发性结直肠癌预后较差。恩考芬尼、比美替尼和西妥昔单抗于2020年在日本被批准用于治疗这种癌症。在此，我们报告一例BRAF V600E突变阳性结直肠癌患者的病例，该患者在我院接受恩考芬尼、比美替尼和西妥昔单抗治疗时发生了3级胰腺炎。胰腺炎治疗后，恩考芬尼剂量从300 mg减至225 mg，比美替尼剂量从90 mg减至60 mg，然后恢复治疗。此后，未观察到3级或更高级别的不良事件。虽然使用恩考芬尼和比美替尼后曾有胰腺炎发生的报道，但较为罕见。通过适当降低剂量并关注副作用，该方案被认为对于70岁以上BRAF V600E突变阳性的晚期复发性结直肠癌患者的长期治疗是可行的。
